C92.61

HCC Category Mapping

What This Code Means

A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) where the cancer has responded to treatment and is in remission.

Coding Tips

• •Confirm the 11q23-abnormality is documented in cytogenetic or molecular testing results
• •Remission status must be explicitly stated in clinical documentation

Clinical Significance

Acute myeloid leukemia with 11q23-abnormality in remission indicates successful treatment response in this cytogenetically defined AML subtype. The prognosis in remission depends on the specific KMT2A fusion partner, with t(9;11)(p22;q23)/KMT2A-MLLT3 carrying a more favorable outlook than other 11q23 rearrangements. Post-remission therapy decisions are guided by the specific cytogenetic and molecular risk stratification.

Documentation Requirements

• ✓Documentation must confirm the 11q23/KMT2A rearrangement and explicitly state remission status with supporting bone marrow and blood count evidence.
• ✓The specific fusion partner, minimal residual disease assessment, and risk stratification should be documented.
• ✓Post-remission therapy plan (consolidation chemotherapy vs.
• ✓allogeneic transplant based on risk group) and surveillance schedule must be recorded.

Commonly Confused Codes